AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03483753
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Blinded Norepinephrine will be started if there is persistent hypotension, characterized by mean arterial pressure \<65 mmHg after fluid replacement. Continuous infusion of the drug at doses ranging from 0.1 mcg / kg / min to 1.0 mcg / kg / min.
Trial: NCT05103878
Drug: BT051 700mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 700mg BT051
Trial: NCT05103878
Drug: BT051 1500mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 1500mg BT051
Trial: NCT05103878
Drug: BT051 3500mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 3500mg BT051
Trial: NCT00520923
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken PO (by mouth) QAM (every morning) for up to 4 weeks.
Trial: NCT00520923
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken PO (by mouth) BID (twice daily) for up to 4 weeks.
Trial: NCT04066491
Drug: M7824
RxNorm normalized name: M7824
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received intravenous infusion of M7824 at a dose of 2400 milligrams (mg), once every 3 weeks (Q3W) 2 years (in case of Complete Response), otherwise until criterion pre-sepcified in protocol for discontinuation is met, in combination with intravenous infusion of Gemcitabine and Cisplatin at a dose of 1000 milligram per meter square (mg/m\^2) and 25 mg/m\^2 respectively on Day 1 and Day 8 of 21- day cycle, for 8 cycles every 3 weeks.
Trial: NCT04066491
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received intravenous infusion of M7824 matched placebo, once every 3 weeks (Q3W) until 2 years (in case of CR), otherwise until crtiterion pre-sepcified in protocol for discontinuation is met.
Trial: NCT01931007
Drug: Sterile saline
RxNorm normalized name: Aqua Care Sterile Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacteriostatic 0.9% sodium chloride, preservative free manufactured by Hospira will be injected into the control knee.
Trial: NCT01053871
Drug: midazolam with fentanyl
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: conscious sedation using midazolam with fentanyl
Trial: NCT00270777
Drug: adrenaline, promethazine, hydrocortisone
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05050071
Drug: Allium Sativum
RxNorm normalized name: ALLIUM SATIVUM WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sixty-six permanent mature necrotic incisors associated with apical periodontitis in male children were selected. Teeth were randomly divided into three groups (n=22) according to intra canal medications used; group I: Ca OH2, group II: garlic extract and group III: mixture of Ca OH2 and garlic extract. After access preparation, four microbiological samples (S) were as follows; (S1): were taken before canal instrumentation and irrigation. (S2): after cleaning and shaping, Then, the third samples (S3) and forth samples (S4) were taken after placement of the tested intracanal medications into the corresponding canals, for 7 and 14 days respectively. Total DNA was extracted from microbiological samples and relative quantitive real time PCR reactions were done to quantify the relative gene expression levels (FC) for Streptococcus and Enterococcus faecalis species.
Trial: NCT00625209
Drug: placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo of hydrocortisone as an iv bolus every 6 hours for seven days plus placebo of fludrocortisone given through the nasogastric tube once a day for seven days plus placebo of activated protein C given as a continuous infusion for 96 hours
Trial: NCT00633256
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo for subjects randomized to placebo arm. Given in two experimental sessions separated by approximately one week.
Trial: NCT00309881
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00625209
Drug: hydrocortisone and fludrocortisone and placebo
RxNorm normalized name: fludrocortisone and antiinfectives
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hydrocortisone will be given as 50mg iv bolus every 6 hours for seven days and a tablet of 50µg of fludrocortisone will be given once a day via the nasogastric tube for seven days and a placebo of activated protein C will be given as a continuous infusion for 96 hours
Trial: NCT03584919
Drug: doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients received oral doxycycline 100 milgrams bid for 15 days
Trial: NCT00876395
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus placebo was administered in a continuous oral daily dosing of 10 mg (two 5-mg tablets).
Trial: NCT00625209
Drug: recombinant human activated protein C and hydrocortisone and fludrocortisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 96 hours continuous infusion of 24µg/kg/h of activated protein C plus seven day treatment with 50mg iv bolus of hydrocortisone every 6 hours and 50µg of fludrocortisone via the nasogastric tube once a day
Trial: NCT00005785
Drug: GCSF Mobilized Allogeneic PBSC Cultured w/Cytokines; Transduced w/RV
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00089661
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg (1.0 mL) administered subcutaneously every six months, beginning on Study Day 1, for a total treatment period of 24 months
Trial: NCT03227471
Drug: TEZ/IVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TEZ/IVA fixed-dose combination for oral administration.
Trial: NCT03227471
Drug: Matched Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo.
Trial: NCT00349375
Drug: Fenofibrate/Simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Fenofibrate 145mg and Simvastatin 20mg
Trial: NCT00349375
Drug: Fenofibrate/Simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Fenofibrate and Simvastatin 40 mg
Trial: NCT00349375
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg
Trial: NCT02681536
Drug: HMG
RxNorm normalized name: HMG-CoA reductase
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00418990
Drug: Multivitamin/Mineral supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03757325
Drug: DNL747
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNL747
Trial: NCT03757325
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02903901
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg liquid Melatonin IR-SL at 7 pm for 1 week
Trial: NCT02903901
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg liquid placebo at 7 pm for 1 week
Trial: NCT01901575
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with established PVC's , sedated with remifentanil IVPCA per study protocol
Trial: NCT03101540
Drug: Omega-3 PUFA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects received 2.2g of eicosapentaenoic acid (EPA) and 1.2g of docosahexaenoic acid (DHA) daily for the duration of the study.
Trial: NCT00957528
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly im injections of 100 mg testosterone enanthate.
Trial: NCT00957528
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly IM injections of sesame oil.
Trial: NCT01110473
Drug: ABT-348
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An oral dose of ABT-348, once daily on Day 1, Day 8, and Day 15 of each 28 day cycle.
Trial: NCT01110473
Drug: ABT-348
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An oral dose of ABT-348, twice daily on Day 1, Day 8, and Day 15 of each 28 day cycle
Trial: NCT01110473
Drug: ABT-348
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An intravenous dose of ABT-348, once daily on Day 1, Day 8, and Day 15 of each 28 day cycle.
Trial: NCT00543010
Drug: MK0767
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04940104
Drug: Botox Injectable Product
RxNorm normalized name: Botox Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botox is a well known neurotoxin that is derived from the bacterium clostridium botulinium. Its therapeutic applications are variable and well documented, alongside its cosmetic applications. There are seven known serotypes of Botox, from A to G, but only two types; A \&B, are available for medical and cosmetic uses.
Trial: NCT01237730
Drug: Tailored antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Select the prophylactic antibiotics according to the patients oropharyngeal microorganism.
Trial: NCT00794963
Drug: Pravastatin, Fenofibrate, Metformin, Orlistat, irbesartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention in the 4 patients consisted in dietary recommendations, advice regarding increasing physical activity, and use of Orlistat 60 mg three times daily. No other drugs were prescribed.
Trial: NCT00496457
Drug: Experimental
RxNorm normalized name: WA-001 Experimental Soil Surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules of TRO19622 (125 mg)- Once a day before noon meal during 6 weeks
Trial: NCT01021956
Drug: STAKEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label,safety and exploratory efficacy study in subjects with active CNV followed for 12 weeks.During first stage(dose escalating stage) subjects assigned to group 1 to 4 will receive a single treatment of VTP at one of three light levels and one of two Drug Light Interval (DLI).Second stage(dose confirmation)will be only initiated at a dose level in which an effect has been seen at week 1 and there is a maximum of one Dose Limiting Toxicity (DLT) out of three subject at week 5.
Trial: NCT01620931
Drug: RO5469754
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single ascending doses, iv or sc
Trial: NCT01620931
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses, iv or sc
Trial: NCT00496457
Drug: Placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 Capsules of PBO per day before noon meal
Trial: NCT04090008
Drug: Saline dressing
RxNorm normalized name: Dermagran Zinc-Saline Dressing 8x4"
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline is used for dressing of the ulcer twice a week
Trial: NCT02463409
Drug: Theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24 hour infusion of IV theophylline
Trial: NCT00483301
Drug: ABI-007(Abraxane)
RxNorm normalized name: PICEA ABIES WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dosage
Trial: NCT00338039
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemoradiation (to start 2-3 weeks post completion of oxaliplatin and gemcitabine): 825 mg/m\^2 by mouth (PO) twice daily Monday-Friday throughout radiation.
Trial: NCT00360594
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 pills (666mg) for 1998mg/day
Trial: NCT03118232
Drug: Iodophor (10% povidone-iodine)
RxNorm normalized name: iodophors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal decolonization using topical 10% povidone-iodine nasal swabs will be applied to all residents on admission for 5 days twice daily plus every other week Monday-Friday using a twice daily regimen.
Trial: NCT03702985
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 625mg/m2 bid Monday-Friday per week
Trial: NCT02947672
Drug: Intraperitoneal Dexamesathone
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02466711
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double blind Placebo will be delivered three times by injection during the course of the study
Trial: NCT03045861
Drug: GSK2838232
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2838232 capsules will be supplied as swedish orange, unmarked capsule (50 mg), and white, unmarked capsules (10 mg) in high-density polyethylene bottles.
Trial: NCT00905931
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: starch
Trial: NCT04089592
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intravenous fentanyl at 2mcg/kg in 100ml saline
Trial: NCT00226109
Drug: spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg once daily. Can be reduced to 50 mg a day still maintaining the doubled-blinded status
Trial: NCT04152577
Drug: R2-combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R2-CHOP/CHOPE/DA-EPOCH/HD MTX~R2-CHOP :~lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0 Cyclophosphamide 750mg / m2 d1, doxorubicin 70mg / m2 or Doxorubicin liposome 30-40 mg / m2 d2, vincristine 1.4mg / m2 or vindesine 3mg / m2 d2, prednisone 100mg d1-5~R2-DA-EPOCH:~lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0 Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5;~R2-HD MTX:~lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0； MTX 3.5g／ｍ２,ｄ1
Trial: NCT04152577
Drug: R-combination chemotherapy
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-CHOP/CHOPE/DA-EPOCH/HD MTX~R-CHOP :~Rituximab：375mg/m2，ivgtt，D0 Cyclophosphamide 750mg / m2 d1, doxorubicin 70mg / m2 or Doxorubicin liposome 30-40 mg / m2 d2, vincristine 1.4mg / m2 or vindesine 3mg / m2 d2, prednisone 100mg d1-5~R-DA-EPOCH:~Rituximab：375mg/m2，ivgtt，D0 Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5;~R-HD MTX:~Rituximab：375mg/m2，ivgtt，D0； MTX 3.5g／ｍ２,ｄ1
Trial: NCT01526330
Drug: YH14618
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A mg/disc
Trial: NCT01526330
Drug: YH14618
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B mg/disc
Trial: NCT01526330
Drug: YH14618
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C mg/disc
Trial: NCT01526330
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0mg/disc
Trial: NCT01349465
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment was given to patients during this study as this is a follow-up study of previous Phase IIb or Phase III in which they received a TMC435-containing regimen.
Trial: NCT02571296
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT03382925
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL of normal saline to be used as steroid diluent in group #2 cervical interlaminar procedure.
Trial: NCT04656223
Drug: FDC therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There is no treatment allocation. Patients administered FDC therapy by prescription that have started before inclusion of the patient into the study will be enrolled.
Trial: NCT03878459
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PATIENTS WILL RECEIVE PLACEBO
Trial: NCT02113436
Drug: FP/ SLM HFA MDI 50/25 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metered-dose aerosol product containing 50 mcg of fluticasone propionate and 25 mcg of salmeterol per inhalation
Trial: NCT03568474
Drug: Glass Ionomer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indirect pulp capping material
Trial: NCT03664882
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: tablet Route of administration: oral
Trial: NCT00865059
Drug: NEURONTIN® 800 mg Tablets, single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B: Active comparator Subjects received Parke-Davis formulated products under non-fasting conditions
Trial: NCT01860521
Drug: Drug used for analgesia procedures
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine (Chirocaine®, Abbott, Chicago, IL, USA) and sufentanil(Fentatienil®, Angelini, Rome, Italy) were administered in both study groups according to the regimen of each intervention arm (Programmed Intermittent Epidural Bolus Versus Continuous Epidural Infusion).
Trial: NCT01860521
Drug: Drug used for termination of pregnancy procedure.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemeprost pessaries.
Trial: NCT00629590
Drug: AzaSite®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ophthalmic solution; 1 drop in each eye BID for two days, then 1 drop in each eye QD for \~12 days
Trial: NCT00478179
Drug: Transdermal/Patch (Bupivacaine TTS [Eladur™])
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02214615
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00695448
Drug: GSK1059615
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1059615 is dosed orally once daily for 21 days of a 28-day cycle. Patients continue treatment for subsequent cycles as long as eligible and receiving benefit.
Trial: NCT00960661
Drug: Insulin/ Glargine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00984971
Drug: HEC Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel applied rectally
Trial: NCT00843388
Drug: placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablet 25 mg OD
Trial: NCT02413320
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02413320
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04492774
Drug: Steroid injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epidural injections
Trial: NCT04080622
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl 0,9% (IV infusion)
Trial: NCT00914251
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of oral Placebo, 500 mg/daily
Trial: NCT04168944
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill manufactured to mimic Lenvatinib 10mg tablet
Trial: NCT00816426
Drug: Kanamycin
RxNorm normalized name: Kanamycin
DrugBank: Kanamycin (DB01172)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Kanamycin (KM) is an aminoglycoside antibiotic belonging to the same class of drugs as Streptomycin, one of the first drugs used to treat TB in the 50 s. It kills sensitive bacteria by binding to the 30S ribosomal subunit and interfering with protein synthesis. Its MIC and MBC against MTB are 2 and 6 g/mL, respectively, with a remarkably low MBC/MIC ratio. However, KM is only used to treat serious bacterial infections due to severe renal toxicity and ototoxicity. No interaction with the metabolism of other drugs has been reported. The drug is approved by the Korean Ministry of Food and Drug Safety (MFDS) but not the US FDA for use against pulmonary TB.
Trial: NCT04622332
Drug: SIR1-365
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Route of administration: oral
Trial: NCT04622332
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Route of administration: oral
Trial: NCT04502251
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The capsule presented the same format, size and color as LDN capsules, however the excipient used was starch.
Trial: NCT02690155
Drug: VKA (Vitamin K antagonist)
RxNorm normalized name: Vitamin K antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As prescribed by treating physicians
Trial: NCT02963116
Drug: AZD5718 IR tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02963116
Drug: AZD5718 oral suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02963116
Drug: Rosuvastatin tablet
RxNorm normalized name: Rosuvastatin Tablets
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03742180
Drug: sublingual ketorolac
RxNorm normalized name: ketorolac Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient will receive sublingual ketorolac in a dose of 0.5 mg.kg-1 in a volume of 1 ml and 1 ml intranasal saline 0.9%
Trial: NCT00823407
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a single oral dose of placebo
Trial: NCT01671800
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04070742
Drug: FMX101
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03221751
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is an inert oral capsule identical in appearance to prazosin capsules.
Trial: NCT02969369
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily
Trial: NCT00801164
Drug: Frio Mouth Rinse Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription Mouth Rinse. Rinse with 15ml twice daily then expectorate.
Trial: NCT03986385
Drug: Apatinib Capecitabine Oxaliplatin
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: apatinib 250mg qd po q4w Capecitabine 1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w